Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Price$7.56

Value ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-42.41%

Price vs S&P 500 (4W)-31.01%

VGM Score40.00

Market Capitalization$141.55M

All Metrics

Book Value / Share (Quarterly)$7.12

P/TBV (Annual)0.58x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.15

Price vs S&P 500 (YTD)-15.28%

Net Profit Margin (TTM)-2838.71%

EPS (TTM)$-5.81

10-Day Avg Trading Volume1.15M

EPS Excl Extra (TTM)$-5.81

EPS (Annual)$-3.64

ROI (Annual)-28.08%

Net Profit Margin (5Y Avg)-2138.37%

Cash / Share (Quarterly)$7.79

ROA (Last FY)-25.66%

EBITD / Share (TTM)$-6.00

ROE (5Y Avg)-324.10%

Operating Margin (TTM)-4309.68%

Cash Flow / Share (Annual)$-3.66

P/B Ratio1.12x

P/B Ratio (Quarterly)1.32x

Net Income / Employee (Annual)$-1,111,100

EV / Revenue (TTM)74.77x

Net Interest Coverage (TTM)-14.44x

ROA (TTM)-61.78%

EPS Incl Extra (Annual)$-3.64

Current Ratio (Annual)8.07x

Quick Ratio (Quarterly)7.64x

3-Month Avg Trading Volume0.34M

52-Week Price Return-14.09%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.07

P/S Ratio (Annual)160.85x

Asset Turnover (Annual)0.01x

52-Week High$20.56

Operating Margin (5Y Avg)-2440.93%

EPS Excl Extra (Annual)$-3.64

CapEx CAGR (5Y)-57.07%

Tangible BV CAGR (5Y)-10.60%

26-Week Price Return-34.49%

Quick Ratio (Annual)7.92x

13-Week Price Return-5.74%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.92x

Enterprise Value$115.89M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)24.74%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-5186.36%

Cash / Share (Annual)$9.27

3-Month Return Std Dev103.86%

Net Income / Employee (TTM)$-2,348,000

ROE (Last FY)-28.08%

Net Interest Coverage (Annual)-12.93x

EPS Basic Excl Extra (Annual)$-3.64

Receivables Turnover (TTM)1.11x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.81

ROI (TTM)-70.89%

P/S Ratio (TTM)91.32x

Pretax Margin (5Y Avg)-2138.37%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.91

Price vs S&P 500 (52W)-38.46%

Year-to-Date Return-7.13%

5-Day Price Return-2.45%

EPS Normalized (Annual)$-3.64

ROA (5Y Avg)-79.97%

Net Profit Margin (Annual)-5186.36%

Month-to-Date Return-4.42%

Cash Flow / Share (TTM)$-10.98

EBITD / Share (Annual)$-4.40

Operating Margin (Annual)-6362.50%

LT Debt / Equity (Annual)0.48x

ROI (5Y Avg)-271.09%

LT Debt / Equity (Quarterly)2.67x

EPS Basic Excl Extra (TTM)$-5.81

P/TBV (Quarterly)61.73x

P/B Ratio (Annual)0.97x

Pretax Margin (TTM)-2838.71%

Book Value / Share (Annual)$8.38

Price vs S&P 500 (13W)-13.99%

Beta2.64x

Revenue / Share (TTM)$0.00

ROE (TTM)-70.89%

52-Week Low$6.72

vGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.23est. -1.24

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.31

4.38

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRBPCorbus Pharmaceuticals Holdings, Inc.	D	—	C	$7.56
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Corbus Pharmaceuticals is a biopharmaceutical company developing precision therapeutics for oncology and metabolic disorders. Its pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4 in cancer; CRB-601, an anti-integrin antibody designed to block TGF activation; and CRB-913, a CB1 receptor inverse agonist for obesity. These programs target validated biological pathways to address serious diseases.